Elanco Animal Health reports 11% revenue growth for third quarter 2026
Elanco Animal Health posted third-quarter revenue of $1.265 billion, driven by increased pricing and organic growth, prompting an upward revision of its annual financial outlook.
Elanco Animal Health announced its third-quarter 2026 financial results, recording $1.265 billion in revenue. This represents an 11% increase compared to the same period last year, a performance supported by organic constant currency growth and margin expansion.
Following the results, the company raised its full-year financial guidance and increased its innovation targets. Management attributed the growth to effective pricing strategies and operational efficiencies that helped drive gross margin improvements.
The firm also reached a milestone regarding its capital structure, reporting a net leverage ratio of 2.9x. This reduction in debt follows an ongoing effort to strengthen the balance sheet while continuing to invest in research and development for its portfolio of animal health products.
Looking ahead, the revised annual outlook suggests sustained demand across Elanco's core veterinary and livestock sectors, positioning the firm to meet its updated year-end performance goals.